Dimerix Limited · ASX:DXB
Dimerix — Monsoon Twilight Investor Briefing, Melbourne, May 2025
18 slides from Dimerix's conference presentation, May 20, 2025
Slide 1: Dimerix to present at Melbourne Twilight Investor Briefing
For Immediate Release DIMERIX TO PRESENT AT MELBOURNE TWILIGHT INVESTOR BRIEFING MELBOURNE, Australia, 20 May 2025: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company with late-stage clinical assets, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be pr
Slide 2: About FSGS Phase 3 Study, Dimerix and DMX-200
About FSGS Phase 3 Study The Phase 3 study, which is titled “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis”, or ACTION3 for short, is a pivotal (Phase 3), multi- centre, randomized, double-blind, placebo-controlled study of the efficacy and sa
Slide 3: Dimerix Forward Looking Statement
relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up
Slide 4: Twilight Briefing May 2025
ACTIONS @ Dimerix Twilight Briefing 20 May 2025 Authorised for lodgement by the Board of the Company
Slide 5: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. = Cc Although we believe that the expectations reflected in the forward looking statements are reasonable je) at this time, Dimerix can give no assurance that these expectati
Slide 6: Overview
Overview | Phase 3 ur commercial licensing deals: a “AU$1.4 billion in total upfront & potential development and sales milestone payments plus royalties? Global Opportunity Lead Drug Candidate * DMX-200 is currently in a Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS) * DMX-200
Slide 7: Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS) = Krcney veselshave towork Focal some Existing blood pressure medication harder under high pressure targets Step 1: angiotensin receptor if 4 ‘oo py 200 interrupts Step 2-the = i blocker (ARB) lowers blood pressure" igh blo inflammatory pathway to target Seg
Slide 8: Significance of stabilising eGFR curve: primary endpoint
Significance of stabilising eGFR curve: primary endpoint Natural aging kidney * Kidney function can be measured using estimated function slope" = P glomerular filtration rate (eGFR): fo) o how many millilitres of blood is filtered by the oO” FSGS slope — kidney kidney per minute g ven is sie) q * eG
Slide 9: Why are kidneys important? Symptoms of proteinuria
Why are kidneys important? Symptoms of proteinuria For personal use only • • • ➢
Slide 10: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoints Gasper a] - : . A F ° veoh >t Clinically meaningful outcomes achieved for patients,2% with no safety issues atgre Cc ai q 12) =) y reduction in —_ 6 proteinuria could yield years oO _ VK of preserved native kidney Cc iL function and delay the [e)
Slide 11: ACTION3 Phase 3 clinical trial — next steps
@} ACTI 3 phase 3 clinical trial — next steps FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB 286 191 43 Total number of patients required - anticipated H2 Patients enrolled over into At Patien
Slide 12: ACTION3 endpoints
Oo ACTIXAN3 endpoints FSGS CLINICAL STUDY Positive Type C meeting held in March 2025 with US Food & Drug Administration (FDA) on proteinuria trial endpoints, and potential for accelerated approval for DMX-2003 je) ( FDA confirmed that a proteinuria-based endpoint for full marketing approval in the U
Slide 13: Key elements of Amicus partnership
Key elements of Amicus partnership Amicus acquires exclusive license to commercialise DMX-200 for all indications in United States Amicus will be responsible for preparation, submission and maintenance D IMerx Ke) receive. of the regulatory dossier in the United States, as well as all sales and cost
Slide 14: Licensing deals collectively valued up to AU$1.4 billion
Licensing deals collectively valued up to “AU$1.4 onne billion in total upfront and potential milestone fees plus royalties! Over AU$60 million in total upfront payments Summary of licensing deals for DMX-200 to date merix has successfully partnered DMX-200 across key markets > Cc 2 2 a2 a rs) Amicu
Slide 15: Potential for additional partnering opportunities
Potential for additional partnering opportunities ADVA\NZ PHARMA Amicus A ¥ FUSO Therapeutics Onal use only Significant potential additional global value remains, as Dimerix pursues and progresses licensing ‘ \ opportunities with potential partners outside the licensed Pa territories, including in M
Slide 16: Corporate overview
Corporate overview gg __ MMi) shane a Cash Balance (Mar25)* $17 million ce =] ; , ot j= Fi Market Capitalisation’ $324 million 2. eM yl * j = 20 fe “4 Share price! $0.56 oo wd “Maui i bhi: Totalordinanyicharestonilesuel 578,623,955 : Vaile shit sdinohu tl ahead ab A ih . eonot teow tak cms mse Avera
Slide 17: Potential catalysts
Potential catalysts 2025 Q1/Q2 2025 * Confirmed FDA meeting to discuss alternative endpoints! * “AU$41 million? development milestone anticipated from FUSO' Q3/Q4 2025 * Planned blinded interim data collection anticipated in H2 20253 * Potential for accelerated (or conditional) approval submission,
Slide 18: Well positioned to deliver against strategic plan
wy Dimerix (ASX:DXB) SCAN ME WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN ESG Statement Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle ofits programs, processes and decision making. The Dimerix commitment to improve its
Dimerix — Monsoon Twilight Investor Briefing, Melbourne, May 2025 on 6ix